Exploring the complexities of pain phenotypes: OMERACT 2023 chronic pain working group workshop
- PMID: 38128175
- DOI: 10.1016/j.semarthrit.2023.152342
Exploring the complexities of pain phenotypes: OMERACT 2023 chronic pain working group workshop
Abstract
Objective: To educate and discuss pain mechanisms (nociceptive, neuropathic, nociplastic) illuminating its possible impact when measuring different outcomes, which may modify, confound and potentially bias the outcome measures applied across various aspects of Rheumatic Musculoskeletal Diseases (RMDs) clinical trials.
Methods: In the plenary presentations, PM lectured on different pain mechanisms and impact on disease activity assessment. Data from two data sets of RMDs patients, which assessed the prevalence and impact of nociplastic pain were presented and reviewed. Audience breakout group sessions and polling were conducted.
Results: Mixed pain etiologies may differentially influence disease activity assessment and therapeutic decision-making. Polling demonstrated a consensus on the need to assess different types of pain as a phenotype, as it constitutes an important contextual factor (a variable that is not an outcome of the trial, but needs to be recognized [and measured] to understand the study results), and to standardize across RMDs.
Conclusion: There is need for a standardized pain measure that can differentiate underlying pain mechanisms.
Keywords: Chronic pain; Measurement; Neuropathic; Nociceptive; Nociplastic; OMERACT.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mary Cowern Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid - Leadership role - Head of Nations at Versus Arthritis - Paid role Lee S Simon Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid - Chair of OMERACT Finance Committee Caitlin M P Jones Grants or contracts from any entity - Awarded seed funding grants for unrelated projects from Arthritis Australia, ANZBACK and Wiser healthcare Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events - Contractor to OMERACT for casual research work (not related to this project) Support for attending meetings and/or travel - OMERACT supported me to attend OMERACT 2023 in Colorado USA (economy class flights, accommodation and conference registration) Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid - Member of the ANZMUSC ECR committee, Member of the Sydney University School of Public Health EMCR committee Lara J Maxwell Other financial or non-financial interests - LJM is a paid staff member of OMERACT Beverley Shea Other financial or non-financial interests - OMERACT Senior Methodologist Vibeke Strand All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) - I am a founding member of the executive committee of Outcome Measures in Rheumatology (OMERACT) [1992 – present], an international consensus organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and has received arms-length funding from as many as 36 sponsors. Grants or contracts from any entity - I am a founding member of the executive committee of Outcome Measures in Rheumatology (OMERACT) [1992 – present], an international consensus organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and has received arms-length funding from as many as 36 sponsors. Karine Toupin-April Support for attending meetings and/or travel - OMERACT travel award given to the Shared decision making group to help attend the OMERACT 2023 meeting Philip Mease Grants or contracts from any entity - Acelyrin, Amgen, Bristol Myers Squib, Eli Lilly, Janssen, Novartis, Pfizer, UCB Consulting fees - Acelyrin, Aclaris, Amgen, Bristol Myers Squib, CorEvitas, Eli Lilly, Inmagene, Janssen, Moonlake Pharma, Novartis, Pfizer, UCB, Ventyx Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events - Amgen, Eli Lilly, Janssen, Novartis, Pfizer, UCB Participation on a Data Safety Monitoring Board or Advisory Board - Genascence – DSMB Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis – Executive board, Spondyloarthritis Research and Therapy Network Ernest Choy Grants or contracts from any entity - Bio-Cancer, Biogen, Novartis, Pfizer, Sanofi Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events - Abbvie, Amgen, Asofarma, Biogen, Bristol Myer Squibbs, Chugai Pharma, Eli Lilly, Fresenius Kabi, Galapagos, Janssen, Novartis, Pfizer, Sanofi, UCB Support for attending meetings and/or travel - Galapagos, Janssen, UCB Stock or stock options – Inmedix Receipt of equipment, materials, drugs, medical writing, gifts or other services - Inmedix
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
